Source link : https://www.newshealth.biz/health-news/dlbcl-tucidinostat-plus-r-chop-improves-outcomes/
In previously untreated “double-expresser” patients, combining tucidinostat with standard R-CHOP chemotherapy resulted in better complete response and event-free survival rates than R-CHOP alone. MDedge News Source link : https://www.medscape.com/s/viewarticle/double-expresser-dlbcl-tucidinostat-improved-r-chop-outcomes-2024a1000d7b?src=rss Author : Publish date : 2024-07-18 10:33:31 Copyright for syndicated content belongs to the linked Source.
Author : News Health
Publish date : 2024-07-18 10:33:31
Copyright for syndicated content belongs to the linked Source.
Categories